Attached files
file | filename |
---|---|
S-1 - FORM S-1 - Phio Pharmaceuticals Corp. | b88518sv1.htm |
EX-3.2 - EX-3.2 - Phio Pharmaceuticals Corp. | b88518exv3w2.htm |
EX-4.2 - EX-4.2 - Phio Pharmaceuticals Corp. | b88518exv4w2.htm |
EX-99.2 - EX-99.2 - Phio Pharmaceuticals Corp. | b88518exv99w2.htm |
EX-10.9 - EX-10.9 - Phio Pharmaceuticals Corp. | b88518exv10w9.htm |
EX-10.5 - EX-10.5 - Phio Pharmaceuticals Corp. | b88518exv10w5.htm |
EX-10.4 - EX-10.4 - Phio Pharmaceuticals Corp. | b88518exv10w4.htm |
EX-10.3 - EX-10.3 - Phio Pharmaceuticals Corp. | b88518exv10w3.htm |
EX-23.1 - EX-23.1 - Phio Pharmaceuticals Corp. | b88518exv23w1.htm |
EX-99.1 - EX-99.1 - Phio Pharmaceuticals Corp. | b88518exv99w1.htm |
EX-10.11 - EX-10.11 - Phio Pharmaceuticals Corp. | b88518exv10w11.htm |
EX-10.10 - EX-10.10 - Phio Pharmaceuticals Corp. | b88518exv10w10.htm |
Exhibit 4.1
THIS NOTE AND THE SECURITIES UNDERLYING THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE ACT), AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS
COVERED BY AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, A TRANSFER MEETING THE REQUIREMENTS
OF RULE 144 OF THE SECURITIES AND EXCHANGE COMMISSION, OR AN OPINION OF COUNSEL SATISFACTORY TO THE
ISSUER TO THE EFFECT THAT ANY SUCH TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
RNCS, INC.
SECURED CONVERTIBLE PROMISSORY NOTE
Up to $1,421,052.63 | San Francisco, California | |
September 24, 2011 |
For Value Received, RNCS, Inc., a Delaware corporation (the Company),
hereby unconditionally promises to pay to the order of Tang Capital Partners, LP (together with its
successors and assigns, Holder), in lawful money of the United States of America and in
immediately available funds, the principal sum of up to One Million Four Hundred Twenty One
Thousand Fifty Two and 63/100 Dollars ($1,421,052.63), or such lesser amount as the Company may owe
Holder hereunder, as determined in accordance with Section 1.2 (such amount, the
Principal), together with accrued and unpaid interest thereon, each due and payable on
the date and in the manner set forth below.
This Secured Convertible Promissory Note (this Note) is one of a series of Secured
Convertible Notes (collectively, the Notes) executed and delivered in connection with
that certain Securities Purchase Agreement by and among the Company and the purchasers listed on
Annex I thereto (the Investors), dated as of September 24, 2011 (the
Securities Purchase Agreement). Subject to the terms and conditions of the Notes, funds
will be provided to the Company under the Notes in up to three funding tranches of Five Hundred
Thousand Dollars ($500,000) each, with the first tranche to be funded concurrently with the
execution and delivery of the Notes (the First Tranche). The purchasers of the Notes
under the Securities Purchase Agreement other than the Holder are referred to below as the
Other Holders and the Other Holders and the Holder are collectively referred to herein as
the Holders. All capitalized terms used herein and not otherwise defined herein will
have the respective meanings given to them in the Securities Purchase Agreement.
1. Principal Repayment; Security.
1.1 Repayment of this Note will be made in lawful money of the United States of America to
Holder at 4401 Eastgate Mall, San Diego, CA 92121, or at such other place as Holder may designate
in writing. Unless earlier converted pursuant to Section 4 hereof, the Principal and
accrued and unpaid interest will be due and payable in cash on the earlier to occur of (the
Maturity Date): (i) 150 days from the date set forth above, or (ii) an Event of Default
(as defined below). This Note is secured by certain collateral of the Company and RXi
(defined below) and subject to a guaranty, as described in that certain: (a) Security Agreement,
dated
1
September 24, 2011, by and between the Company and Tang Capital Partners, LP as agent (the
Agent); (b) Pledge, Assignment and Security Agreement, dated September 24, 2011, by and
between RXi Pharmaceuticals Corporation, a Delaware corporation (RXi); and the Agent, and
(c) General Continuing Guaranty, dated September 24, 2011, by and between RXi and the Agent.
1.2 The Principal due under Section 1.1 shall be equal to: (x) Four Hundred Seventy
Three Thousand Six Hundred Eighty Four and 21/100 Dollars ($473,684.21), which sum the Holder has
lent to the Company concurrent with the execution of this Note (the First Tranche Loan
Amount), plus (y) the Second Tranche Loan Amount and the Third Tranche Loan Amount (each
defined below), to the extent such sums are lent to the Company in accordance with Section
1.3 of this Note.
1.3 Use of Proceeds; Additional Tranches.
1.3.1 The funds provided by the Holders in the First Tranche will be used to fund the
Companys operations pursuant to the budget attached hereto as Annex A (the Initial
Budget). Subject to the approval of the Second Tranche Budget and the Third Tranche Budget
(each defined below), the Holders will provide up to two additional funding tranches of Five
Hundred Thousand Dollars ($500,000) each, as set forth below.
1.3.2 Within fifteen (15) days prior to the exhaustion of the funds underlying the First
Tranche, the Company will present the Holders with an updated budget for their review and approval,
in their sole discretion (the Second Tranche Budget), which budget will detail the
planned use of proceeds for a second tranche of funding under the Notes in the aggregate sum of sum
of Five Hundred Thousand Dollars ($500,000) (the Second Tranche). Upon the Company and
the Requisite Holders (defined below) mutually agreeing upon the use of proceeds under the Second
Tranche Budget, the Holders will fund the Second Tranche, with the Holder under this Note thereupon
being required to lend the Company an additional Four Hundred Seventy Three Thousand Six Hundred
Eighty Four and 21/100 Dollars ($473,684.21) of Principal hereunder (the Second Tranche Loan
Amount). Upon the funding of the Second Tranche Loan Amount, interest will thereafter accrue
on such additional Principal balance, as set forth below in Section 2.
1.3.3 Within fifteen (15) days prior to the exhaustion of the funds underlying the Second
Tranche, the Company will present the Investors with an updated budget for their review and
approval, in their sole discretion (the Third Tranche Budget), which budget will detail
the planned use of proceeds for a third tranche of funding under the Notes in an amount equal to in
the aggregate sum of sum of Five Hundred Thousand Dollars ($500,000) (the Third Tranche).
Upon the Company and the Requisite Holders (defined below) mutually agreeing on the use of
proceeds under the Third Tranche Budget, the Holders will fund the Third Tranche, with the Holder
under this Note thereupon being required to lend the Company an additional Four Hundred Seventy
Three Thousand Six Hundred Eighty Four and 21/100 Dollars ($473,684.21) of Principal hereunder (the
Third Tranche Loan Amount). Upon the funding of the Third Tranche Loan Amount, interest
will thereafter accrue on such additional Principal
balance, as set forth below in Section 2. For purposes of this Note, each of the
Initial Budget, the Second Tranche Budget and the Third Tranche Budget are referred to below as a
Budget.
2
2. Interest Rate. The Company further promises to pay interest on the outstanding
Principal from the date hereof until payment in full, with interest accruing from the Funding Date
(defined below) with respect to each tranche at a rate of seven percent (7.0%) per annum or the
maximum rate permitted by law, whichever is less. Interest will be due and payable on the Maturity
Date and will be calculated on the basis of a 360-day year for the actual number of days elapsed.
Notwithstanding the foregoing, upon the occurrence of an Event of Default, interest shall
thereafter accrue at a rate of eighteen percent (18%) per annum, or the maximum rate permitted by
law, whichever is less. For purposes of this Section 2, the Funding Date shall
mean the respective dates on which the Company receives the First Tranche Loan Amount, the Second
Tranche Loan Amount and the Third Tranche Loan Amount.
3. Prepayment. The Company may not in whole or in part prepay its obligations under
this Note without the prior written consent of Holder.
4. Conversion
4.1 Series A Preferred Conversion. At the Closing, the Principal and accrued interest
due under the Note will automatically convert into fully paid shares (the Conversion
Shares) of Series A Preferred at rate of $1,000 per share. To the extent necessary, the
Company may issue fractional shares of Series A Preferred in issuing the Conversion Shares pursuant
to this Section 4.1.
4.2 Common Stock Conversion. If, as of the Maturity Date, (i) neither the Company nor
the Investors have terminated the Securities Purchase Agreement pursuant to Sections 8.01(d) or
8.01(e), respectively, and (ii) the Closing has not occurred, then, in such case, this Note will be
automatically cancelled as to 50% of the outstanding balance (i.e., Principal and accrued interest)
thereof in exchange for the Companys sale and issuance to the Investors at such time of a number
of shares of Company common stock, par value $0.0001 per share, (the Common Stock)
constituting 51% of the outstanding shares of Common Stock (measured on a Fully-Diluted Basis)
immediately following such issuance, after giving effect to the issuance contemplated by the
Advirna Amendment. The remaining balance due under this Note will be due and payable at the
Maturity Date as set forth herein. For purposes of this Note, Fully-Diluted Basis
includes the issued and outstanding capital stock of the Company, determined on an as-converted
basis, as well as any securities underlying outstanding options, warrants, convertible securities
or future stock issuance obligations, conditional, unconditional or otherwise. In the events
described in clauses (i) and (ii), above, it is intended and agreed that the shares of Company
common stock held by RXi shall constitute 44% of the outstanding shares of Common Stock (measured
on a Fully-Diluted Basis) and that the Company, RXi and the holders shall enter into a customary
form of stockholders agreement under which RXi shall be entitled to designate one or more members
of the Board of Directors of the Company constituting a minority of the members of the Board of
Directors, to receive periodic financial and other information from the Company, tag-along (and
drag-along) rights in connection with proposed sales or other dispositions of capital stock of the
Company, and other protective rights as a
minority stockholder of the Company, all as shall be mutually agreed upon among the Company,
RXi and the holders.
4.3 Delivery of Stock Certificates, Etc.
3
4.3.1 Conversion Pursuant to Section 4.1. If this Note is converted pursuant to
Section 4.1, written notice will be delivered to Holder at the address last shown on the
records of the Company for Holder or given by Holder to the Company for the purpose of notice,
notifying Holder of the conversion to be effected, the principal amount of this Note to be
converted, together with all accrued and unpaid interest, the date on which such conversion is
expected to occur and calling upon Holder to surrender to the Company, in the manner and at the
place designated, this Note. Upon such conversion of this Note, Holder agrees to deliver the
original of this Note (or a notice to the effect that the original Note has been lost, stolen or
destroyed and an agreement acceptable to the Company whereby the Holder agrees to indemnify the
Company from any loss incurred by it in connection with this Note) at the Closing for cancellation;
provided, however, that at such time, this Note will be deemed converted and of no
further force and effect, whether or not it is delivered for cancellation as set forth in this
sentence. The Company will, as soon as practicable thereafter, issue and deliver to Holder a
certificate or certificates for the number of shares to which Holder will be entitled upon such
conversion.
4.3.2 Conversion Pursuant to Section 4.2. If this Note is converted pursuant to
Section 4.2, written notice will be delivered to Holder at the address last shown on the
records of the Company for Holder or given by Holder to the Company for the purpose of notice,
notifying Holder of the conversion to be effected, the amount of this Note to be converted (taking
into account all accrued and unpaid interest), the date on which such conversion is expected to
occur and the remaining balance due under the Note. The written notice shall also call upon Holder
to surrender to the Company, in the manner and at the place designated, this Note and the remaining
balance due under this Note. Upon such conversion of this Note and payment of remaining balance
due, Holder agrees to deliver the original of this Note (or a notice to the effect that the
original Note has been lost, stolen or destroyed and an agreement acceptable to the Company whereby
the Holder agrees to indemnify the Company from any loss incurred by it in connection with this
Note) on the Maturity Date for cancellation; provided, however, that at such time,
as long as the remaining balance due under this Note is paid in full, this Note will be deemed
converted as set forth in Section 4.2 and paid in full and of no further force and effect,
whether or not it is delivered for cancellation as set forth in this sentence. The Company will,
as soon as practicable thereafter, issue and deliver to Holder a certificate or certificates for
the number of shares to which Holder will be entitled upon such conversion.
4.3.3 Any conversion of this Note pursuant to Section 4 will be deemed to have been
made immediately prior to the Closing or the Maturity Date, as applicable, and on and after such
date the persons entitled to receive the shares issuable upon such conversion will be treated for
all purposes as the record Holder of such shares.
5. Default. If any of the following events (hereafter called Events of
Default) occur:
(a) The Company makes a general assignment for the benefit of creditors;
(b) The Company files a voluntary petition in bankruptcy, or becomes insolvent or adjudicated
bankrupt, or files any petition or answer seeking any reorganization, arrangement, composition,
readjustment, liquidation, dissolution or similar relief under the
4
present or any future federal
bankruptcy act or other applicable federal, state or other statute, law or regulation, or files any
answer admitting the material allegation of a petition filed against the Company in such
proceeding, or seeks or consents to or acquiesce in the appointment of any trustee, receiver or
liquidator of the Company of all or any substantial part of the properties of the Company, or the
Company commences the winding up or the dissolution or liquidation of the Company;
(c) Within sixty (60) days after a court of competent jurisdiction has entered an order,
judgment or decree approving any complaint or petition against the Company seeking reorganization,
dissolution or similar relief under the present or any future federal bankruptcy act or other
applicable federal, state or other statute, law or regulation, such order, judgment or decree has
not been dismissed or stayed pending appeal, or, within sixty (60) days after the appointment,
without the consent or acquiescence of the Company, of any trustee, receiver or liquidator of the
Company or of all or any substantial part of the properties of the Company, such appointment has
not been vacated or stayed pending appeal, or if, within sixty (60) days after the expiration of
any such stay, has not been vacated;
(d) The Company or RXi materially breach any representation, warranty or covenant contained in
the Transaction Documents and such breach is not cured (if it can be cured) within five (5)
Business Days after the Investors provide notice of such breach;
(e) The Companys actual aggregate expenditures with respect to any Budget exceed 105% of the
aggregate budgeted amount for that time period covered by such Budget, without the prior approval
of the Investors;
(f) There is a Material Adverse Effect with respect to the Company, the Company or RXi provide
written notice to the Investors that either of them will be unable to satisfy a condition to
Closing set forth in Article V of the Securities Purchase Agreement, or the Securities
Purchase Agreement is terminated by the Investors as permitted under Section 8.01(e)
thereof;
(g) A final judgment or order for the payment of monetary damages or awarding injunctive
relief in connection with the transactions contemplated by the Securities Purchase Agreement is
rendered against the Company and the same remains undischarged for a period of thirty (30) days
during which execution has not been effectively stayed, or any injunction, judgment, writ,
assessment, warrant of attachment, or execution or similar process has been issued or levied
against a substantial part of the property of the Company, if any and such injunction, judgment,
writ, or similar process is not released, stayed, vacated or otherwise dismissed within thirty (30)
days after issue or levy;
then, and in each and every such case, amounts under this Note will be forthwith due and
payable, without presentation, protest or further demand or notice of any kind, all of which are
hereby expressly waived. The Company will give prompt written notice to Holder of the
occurrence of any and all of the foregoing events. In addition to the foregoing remedies, upon the
occurrence and during the continuance of any Event of Default, Holder may exercise any other right
power or remedy granted to it by the Transaction Documents or otherwise permitted to it by law,
either by suit in equity or by action at law, or both.
5
For the purposes of this Note, a Business Day means a day other than a Saturday or a Sunday
on which banks are open for business in New York.
6. Payment. Unless converted into the Companys equity securities pursuant to the
terms hereof, payment will be made in lawful tender of the United States.
7. Waiver. The Company waives presentment and demand for payment, notice of
dishonor, protest and notice of protest of this Note, and will pay all costs of collection when
incurred, including, without limitation, reasonable attorneys fees, costs and other expenses. The
right to plead any and all statutes of limitations as a defense to any demands hereunder is hereby
waived to the fullest extent permitted by law.
8. Assignment. The rights, interests or obligations hereunder may not be assigned, by
operation of law or otherwise, in whole or in part, by the Company without the prior written
consent of Holder.
9. Registration, Transfer and Replacement of the Note. This Note will be a registered
Note. The Company will keep, at its principal executive office, books for the registration and
registration of transfer of this Note. Prior to presentation of any Note for registration of
transfer, the Company will treat the person in whose name such Note is registered as the owner and
Holder of such Note for all purposes whatsoever, whether or not such Note will be overdue, and the
Company will not be affected by notice to the contrary. Subject to any restrictions on or
conditions to transfer set forth herein, the Holder, at its option, may in person or by duly
authorized attorney surrender the same for exchange at the Companys chief executive office, and
promptly thereafter and at the Companys expense, except as provided below, receive in exchange
therefor one new Note, in the principal requested by such holder, dated the date to which interest
will have been paid on the Note so surrendered or, if no interest will have yet been so paid, dated
the date of the Note so surrendered and registered in the name of such person or persons as will
have been designated in writing by such Holder or its attorney for the same principal amount as
then unpaid principal amount of the Note so surrendered. Upon receipt by the Company of evidence
reasonably satisfactory to it of the ownership of and the loss, theft, destruction or mutilation of
any Note and (a) in the case of loss, theft or destruction, of indemnity reasonably satisfactory to
it; or (b) in the case of mutilation, upon surrender thereof, the Company, at its expense, will
execute and deliver in lieu thereof a new Note executed in the same manner as the Note being
replaced, in the same principal amount as the unpaid principal amount of such Note and dated the
date to which interest will have been paid on such Note or, if no interest will have yet been so
paid, dated the date of such Note.
10. Governing Law; Consent to Jurisdiction. This Note and all actions arising out of
or in connection with this Note will be governed by and construed in accordance with the laws of
the State of California, without regard to the conflicts of law provisions of the State of
California
or of any other state. Each of the Company and the Holder (i) hereby irrevocably submits to
the exclusive jurisdiction of the United States District Court sitting in California and the courts
of the State of California for the purposes of any suit, action or proceeding arising out of or
relating to this Note and (ii) hereby waives, and agrees not to assert in any such suit, action or
proceeding, any claim that it is not personally subject to the jurisdiction of such court, that the
suit, action or proceeding is brought in an inconvenient forum or that the venue of the suit,
action
6
or proceeding is improper. Each of the Company and the Holder consents to process being
served in any such suit, action or proceeding by mailing a copy thereof to such party at the
address in effect for notices to it under the Securities Purchase Agreement and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing in this
Section 10 shall affect or limit any right to serve process in any other manner permitted
by law. Each of the Company and the Holder hereby agree that the prevailing party in any suit,
action or proceeding arising out of or relating to this Note shall be entitled to reimbursement for
fees and expenses, including reasonable legal fees, from the non-prevailing party.
11. Notices. All notices and other communications required or permitted hereunder
will be in writing and will be transmitted by e-mail or facsimile, or, if sent within the United
States, mailed by first-class mail, postage prepaid, to the address set forth below the recipients
signature, or at such other address as the recipient will have furnished to the other party in
writing. All notices will be deemed effectively delivered upon transmission or mailing.
12. Amendment. No provision of the Notes may be modified or amended on behalf of all
of the Holders other than by a written instrument signed by the Company and the holders of at least
a majority of the combined principal amount of the then outstanding Notes (the Requisite
Holders); provided that if any of the rights of the Holder under this Note are materially
diminished by such waiver or amendment in a manner that is not similar in all material respects to
the effects on the Other Holders, then such waiver or amendment shall not be effective with respect
to the Holder without the written consent of the Holder. The Holder acknowledges that any
amendment or modification made in compliance with this Section 12 shall be binding on all
Holders of the Notes, including, without limitation, an amendment or modification that has an
adverse effect on any or all Holders. Notwithstanding the foregoing, nothing provided in this
Section 12 shall limit the Holders right to waive or amend any provision of this Note on
its own behalf. No consideration shall be offered or paid to any Holder of Notes to amend or waive
or modify any provision of the Notes unless the same consideration is also offered to all of the
Holders holding Notes on the date of such amendment, waiver or modification, on a pro rata basis
based upon the outstanding Principal amount of the Notes. This provision constitutes a separate
right granted to each Holder by the Company and shall not in any way be construed as the Holders
acting in concert or as a group.
13. Ranking of Notes. The obligations of the Company under the Notes shall be senior
in time and right of payment to all other Indebtedness (defined below) of the Company. Upon
maturity or any Event of Default, the Holder will be entitled to receive, before any distribution
or payment is made upon, or set apart with respect to, any Indebtedness of the Company other than
Indebtedness represented by the Notes, or any class of capital stock of the Company, an amount
equal to the Principal amount plus all accrued and unpaid interest thereon. For purposes of this
Section 13, Indebtedness means (a) all obligations for borrowed money; (b) all
obligations evidenced by bonds, debentures, notes, or other similar instruments and all
reimbursement or other obligations in respect of letters of credit, bankers acceptances,
current swap agreements, interest rate hedging agreements, interest rate swaps, or other financial
products; (c) all capital lease obligations; (d) all obligations or liabilities secured by a lien
or encumbrance on any asset of the Company, irrespective of whether such obligation or liability is
assumed; (e) all obligations for the deferred purchase price of assets, together with trade debt
and other accounts payable; (f) all synthetic leases; (g) any obligation guaranteeing or intended
to
7
guarantee (whether directly or indirectly guaranteed, endorsed, co-made, discounted or sold with
recourse) any of the foregoing obligations of any other person; (h) trade debt; and (i)
endorsements for collection or deposit.
14. Usury. In the event any interest is paid on this Note which is deemed to be in
excess of the then legal maximum rate, then that portion of the interest payment representing an
amount in excess of the then legal maximum rate will be deemed a payment of principal and applied
against the principal of this Note.
[Signature page follows]
8
IN WITNESS WHEREOF, the undersigned has executed this Note as of the date first set forth
above.
RNCS, Inc. |
||||
By: | /s/ Mark J. Ahn | |||
Name: | Mark J. Ahn, Ph.D. | |||
Title: | President and Chief Financial Officer | |||
Agreed and Accepted:
Tang Capital Partners, LP |
||||
By: | /s/ Kevin Tang | |||
Name: | Kevin Tang | |||
Title: | Managing Director | |||
[Signature Page to Note]